[go: up one dir, main page]

AR068810A1 - Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden - Google Patents

Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden

Info

Publication number
AR068810A1
AR068810A1 ARP080103560A ARP080103560A AR068810A1 AR 068810 A1 AR068810 A1 AR 068810A1 AR P080103560 A ARP080103560 A AR P080103560A AR P080103560 A ARP080103560 A AR P080103560A AR 068810 A1 AR068810 A1 AR 068810A1
Authority
AR
Argentina
Prior art keywords
benzo
ethylsulfonyl
naphthalen
oxazole
polymorphic form
Prior art date
Application number
ARP080103560A
Other languages
English (en)
Inventor
Shabana Ahmed
Mark William Hooper
Alexander Charles Weymouth-Wilson
Karen June Etherington
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of AR068810A1 publication Critical patent/AR068810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 5: Una forma polimorfica del compuesto 5-(etilsulfonil)-2-(naftalen-2-iI)benzo[d]oxazol (forma polimorfica 1) caracterizada porque provee un patron de difraccion de polvo de rayos X que comprende picos a 14,5 +- 0,2, 16,7 +- 0,2, 19,1 +- 0,2 y 24,0 +- 0,2. Reivindicacion 19: Una forma polimorfica del compuesto 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol (forma polimorfica 3) caracterizada porque provee un patron de difraccion de polvo de rayos X que comprende picos a 12,1 +- 0,2, 17,4 +- 0,2, 22,7 +- 0,2, 25,0 +- 0,2 y 26,5 +- 0,2. Reivindicacion 26: Una forma polimorfica del compuesto 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol (forma polimorfica 4) caracterizada porque provee un patron de difraccion de polvo de rayos X que comprende picos a 14,6 +- 0,2, 16,1 +- 0,2, 17,0 +- 0,2, 19,3 +- 0,2 y 29,2 +- 0,2. Reivindicacion 33: Un proceso para sintetizar una forma polimorfica del compuesto 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol de acuerdo con cualquiera de las reivindicaciones 1 a 9 caracterizado porque comprende los pasos de: (i) disolver 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol en acetona y a continuacion agregar IPA hasta que se forma un producto solido donde la relacion de acetona : IPA es 20 : 80; o disolver 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol en EtOAc y a continuacion agregar IPA hasta que se forma un producto solido donde la relacion de EtOAc : IPA es 40 : 60; o disolver 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol en DMF y a continuacion agregar IPA hasta que se forma un producto solido donde la relacion de DMF : IPA es 40 : 60; o disolver 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol en acetona y a continuacion agregar EtOH hasta que se forma un producto solido donde la relacion de acetona : EtOH es 40 : 60; o disolver 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol en acetona a reflujo y a continuacion enfriar hasta -10sC a -15sC hasta que se forma un producto solido; y a continuacion (ii) separar el producto solido.
ARP080103560A 2007-08-15 2008-08-14 Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden AR068810A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
AR068810A1 true AR068810A1 (es) 2009-12-09

Family

ID=38566447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103560A AR068810A1 (es) 2007-08-15 2008-08-14 Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden

Country Status (17)

Country Link
US (2) US20090048314A1 (es)
EP (2) EP2176246A2 (es)
JP (2) JP2010535829A (es)
KR (1) KR20100075777A (es)
CN (2) CN101896475A (es)
AR (1) AR068810A1 (es)
AU (2) AU2008286324A1 (es)
BR (2) BRPI0811548A2 (es)
CA (2) CA2685939A1 (es)
CL (1) CL2008002391A1 (es)
GB (1) GB0715937D0 (es)
IL (1) IL201908A0 (es)
MX (2) MX2009011916A (es)
PE (1) PE20090604A1 (es)
RU (1) RU2009141831A (es)
TW (1) TW200911767A (es)
WO (2) WO2009021748A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
KR20190026647A (ko) 2016-03-30 2019-03-13 서밋 (옥스포드) 리미티드 뒤쉔 근육 영양장애의 치료용 조성물
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
EP4403171A3 (en) 2017-06-19 2024-09-11 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (es) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
DE59206989D1 (de) * 1991-08-08 1996-10-02 Ciba Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
ES2157268T5 (es) * 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
WO1996000560A2 (en) * 1994-06-30 1996-01-11 Minnesota Mining And Manufacturing Company Dental impression material with cure-indicating dye
AU3002495A (en) * 1994-06-30 1996-01-25 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
EP1177179A1 (de) * 1999-05-07 2002-02-06 Basf Aktiengesellschaft Benzoheterocyclylcyclohexenone und ihre verwendung als herbizide
CA2373293A1 (en) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft 4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
AU7320100A (en) * 1999-09-24 2001-04-24 Ono Pharmaceutical Co. Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US7361678B2 (en) * 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
CN1285601C (zh) * 2000-11-30 2006-11-22 佳能株式会社 发光器件和显示器
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CA2496633A1 (en) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US20040242673A1 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
CN1882879B (zh) * 2003-09-22 2010-08-11 爱克发印艺公司 可光聚合的组合物
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
AU2005211255A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
KR100718765B1 (ko) * 2004-08-19 2007-05-15 주식회사 엘지화학 버퍼층을 포함하는 유기 발광 소자 및 이의 제작 방법
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7893267B2 (en) * 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
JP5001949B2 (ja) * 2005-12-02 2012-08-15 サッチェム，インコーポレイテッド 陰イオン交換置換クロマトグラフィー方法および陰イオン交換置換クロマトグラフィー方法における置換剤化合物として用いられる陰イオン性有機化合物
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
US20090048314A1 (en) 2009-02-19
JP2010535829A (ja) 2010-11-25
AU2008286324A1 (en) 2009-02-19
GB0715937D0 (en) 2007-09-26
CL2008002391A1 (es) 2009-05-22
CN101896475A (zh) 2010-11-24
AU2008286325A1 (en) 2009-02-19
EP2188270A2 (en) 2010-05-26
PE20090604A1 (es) 2009-05-16
RU2009141831A (ru) 2011-05-20
BRPI0811315A2 (pt) 2015-01-27
WO2009021748A2 (en) 2009-02-19
MX2009011967A (es) 2009-11-19
WO2009021749A8 (en) 2009-09-11
WO2009021749A3 (en) 2009-04-02
EP2176246A2 (en) 2010-04-21
JP2010535830A (ja) 2010-11-25
KR20100075777A (ko) 2010-07-05
US20100267961A1 (en) 2010-10-21
WO2009021748A3 (en) 2009-04-02
CA2685590A1 (en) 2009-02-19
CA2685939A1 (en) 2009-02-19
CN101679323A (zh) 2010-03-24
US8138351B2 (en) 2012-03-20
WO2009021749A2 (en) 2009-02-19
BRPI0811548A2 (pt) 2014-11-18
TW200911767A (en) 2009-03-16
MX2009011916A (es) 2009-11-18
IL201908A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
AR068810A1 (es) Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden
AR119704A2 (es) Forma sólida vítrea de éster metílico de cddo, método para obtenerla, y composiciones farmacéuticas relacionadas
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
CY1121744T1 (el) Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CY1119281T1 (el) Καινοφανεις μακροκυκλοι ως αναστολεις τελεστη xiα
PE20171105A1 (es) Formas solidas de un inhibidor ask1
NO343834B1 (no) Farmasøytisk preparat omfattende en omega-karboksylarylsubstituert difenylurea for behandling av cancer
AR081226A1 (es) Polimorfo cristalino de 4-[5-[3-cloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-[2-oxo-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenocarboxamida
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
EA200870103A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
NO20081636L (no) FAP - inhibitorer
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
WO2008091670A3 (en) Organic semiconductor materials and precursors thereof
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
BRPI0811816A2 (pt) "forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem"
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
EP1872711A4 (en) SOLID COSMETIC PIN AND METHOD FOR THE PRODUCTION THEREOF
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal